
    
      Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study,
      comparing budesonide pMDI 160 ï¿½g bid with placebo: a 6-week efficacy and safety study in
      children aged 6 to <12 years with asthma
    
  